Acoramidis hydrochloride NEW
| Price | $48 | $123 | $198 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-09 |
Product Details
| Product Name: Acoramidis hydrochloride | CAS No.: 2242751-53-5 |
| Purity: 99.57% | Supply Ability: 10g |
| Release date: 2025/11/09 |
Product Introduction
Bioactivity
| Name | Acoramidis hydrochloride |
| Description | Acoramidis hydrochloride (Alxn2060 hydrochloride) is an orally active and selective kinetic stabilizer of WT and V122I- TTR (transthyretin) . Acoramidis hydrochloride is used in the study for transthyretin amyloidosis. |
| In vitro | Acoramidis (AG10, 0.1-10 μM for TTR ～5 μM) stabilizes V122I- and WT-TTR effectively, outperforming their efficacy in whole serum [1]. Acoramidis (AG10) stimulates mitochondrial QO2 concentration-dependently between 10 and 100 μM [3]. It exhibits minimal inhibition of the potassium ion channel hERG (IC50 > 100 μM) and several cytochrome P450 isozymes (IC50 > 50 μM) [low toxicity] [1]. Western Blot Analysis [1], using human serum (TTR ～5 μM), at concentrations of 0.1 and 10 μM, with a 72-hour incubation, shows AG10 is significantly more effective than tafamidis in stabilizing TTR, with 10 μM stabilizing almost all TTR in serum. |
| In vivo | Animal Model: Wistar rats [1] . Dosage: 50 mg/kg/d (Toxicity Analysis). Administration: Oral gavage, daily for 28 d. Result: Showed the plasma C max of ～40 μM and histopathological evaluation of liver, kidney, heart, spleen, thymus, and lung showed no signs of pathologic processes in the Acoramidis-treated animals |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.08 mM), Sonication is recommended. DMSO : 60 mg/mL (182.5 mM), Sonication is recommended. |
| Keywords | Transthyretin | Alxn2060 Hydrochloride | AG-10 Hydrochloride | AG10 Hydrochloride | AG 10 Hydrochloride | Acoramidis Hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2.00/100kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-06-19 | |
| $0.00/1kg |
VIP4Y
|
Dingwang Technology (Wuhan) Co., Ltd.
|
2022-10-28 | |
| $0.00/1kg |
VIP1Y
|
Chongqing Soarwin Technology Co., Ltd
|
2025-04-09 | |
| $0.00/25kg |
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-17 | |
| $0.00/25kg |
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY